Immunovant Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with autoimmune diseases. Utilizing its proprietary technology, Immunovant aims to create monoclonal antibodies that target specific pathways involved in these conditions, with the goal of providing safer and more effective treatment options. The company's research and development efforts are centered on addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from autoimmune disorders. Through its commitment to scientific advancement and patient care, Immunovant actively works to bring novel treatments to the market. Read More
Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjust price targets.
Roivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna.
Matthew Klein, CEO of Roivant, said the company has had “a pret
THOUSAND OAKS, Calif. – In a move that significantly strengthens its hold on the thyroid eye disease (TED) market, Amgen (NASDAQ: AMGN) recently announced pivotal Phase 3 topline results for its subcutaneous (SC) formulation of TEPEZZA (teprotumumab-trbw). The data, released on April 6, 2026, indicates that the subcutaneous version—delivered via
The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that have fundamentally reshaped the competitive landscape for autoimmune treatments. As of April 2, 2026, Roivant has reached a multi-year valuation peak,
Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal update from its Phase 3 CAPTIVATE trial. The company, which specializes in "next-generation" complement inhibitors, announced that its lead candidate, claseprubart (DNTH103), met early responder [...]
As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster" that could sustain their independence. Today, Argenx (NASDAQ: ARGX) has effectively ended that search, cementing its status as a global biopharmaceutical powerhouse. Following its full-year 2025 earnings [...]
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a significant 15% stock surge, a move driven by clinical validation of its diversified "Vant" model. This recent rally—pushing shares toward a yearly high of $24.21—is primarily [...]
Immunovant stock drops 10% despite meeting Q2 FY2026 earnings estimates. The sell-off is driven by investor reaction to clinical pipeline updates for its anti-FcRn therapies.
